EP1027076A2 - Utilisation de vecteurs tels que adenovirus et/ou virus adeno-associes et/ou retrovirus et/ou herpesvirus et/ou liposomes et/ou plasmides comme vehicules d'informations genetiques relatives a l'aptitude des cellules de mammiferes a produire des agents pour le traitement de pathologies osseuses - Google Patents

Utilisation de vecteurs tels que adenovirus et/ou virus adeno-associes et/ou retrovirus et/ou herpesvirus et/ou liposomes et/ou plasmides comme vehicules d'informations genetiques relatives a l'aptitude des cellules de mammiferes a produire des agents pour le traitement de pathologies osseuses

Info

Publication number
EP1027076A2
EP1027076A2 EP98959810A EP98959810A EP1027076A2 EP 1027076 A2 EP1027076 A2 EP 1027076A2 EP 98959810 A EP98959810 A EP 98959810A EP 98959810 A EP98959810 A EP 98959810A EP 1027076 A2 EP1027076 A2 EP 1027076A2
Authority
EP
European Patent Office
Prior art keywords
bone
vectors
cells
use according
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98959810A
Other languages
German (de)
English (en)
Inventor
Axel Wilhelm August Baltzer
Christian Lattermann
Janey Desales Whalen
Paul David Robbins
Christopher Howard Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1997147719 external-priority patent/DE19747719A1/de
Priority claimed from DE1997147718 external-priority patent/DE19747718A1/de
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP1027076A2 publication Critical patent/EP1027076A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • vectors such as adenoviruses and / or adeno-associated viruses and / or retroviruses and / or herpes simplex viruses and / or liposomes and / or piasmids as vehicles for genetic information to enable mammalian cells to produce agents for the treatment of bone pathogens.
  • the invention relates to the use of adenoviruses and / or adeno-associated viruses and / or retroviruses and / or herpes simplex viruses and / or liposomes and / or piasmids as vectors, respective vehicles for genetic information to enable mammalian cells to be therapeutically enabled, to produce proteins, effective as medicinal products, for correcting bone pathologies at the cellular level.
  • the enzyme activity of the luciferase after intraosseous vector application of Ad-Luc is shown in FIG. 4. It demonstrates that transgene expression persists in the bones and muscles over the entire course of the examination interval of 21 days. Transgene expression from the liver (2 days) and draining lymph nodes (14 days) is transient and does not reach the level of enzyme activity in the area of the injection.
  • luciferase activity was found in the bone and bone marrow, as well as in the defect-filling connective tissue and in the surrounding muscle tissue at the injection site. 5 days after the transduction there was a slight luciferase activity in the liver which disappeared completely after 10 days. No luciferase activity could be found in the contralateral femur, the lungs and the spleen (Fig. 8).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de vecteurs tels que adénovirus et/ou virus-adéno associés et/ou rétrovirus et/ou herpèsvirus et/ou liposomes et/ou plasmides, comme agents stimulant les cellules de mammifères en vue de la production de protéines thérapeutiques, agissant comme médicaments, au niveau cellulaire, pour le traitement génétique de pathologies osseuses.
EP98959810A 1997-10-29 1998-10-29 Utilisation de vecteurs tels que adenovirus et/ou virus adeno-associes et/ou retrovirus et/ou herpesvirus et/ou liposomes et/ou plasmides comme vehicules d'informations genetiques relatives a l'aptitude des cellules de mammiferes a produire des agents pour le traitement de pathologies osseuses Ceased EP1027076A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19747718 1997-10-29
DE1997147719 DE19747719A1 (de) 1997-10-29 1997-10-29 Verfahren zur Verbesserung der Knochenheilung mit der molekularbiologischen Methode der Genübertragung
DE19747719 1997-10-29
DE1997147718 DE19747718A1 (de) 1997-10-29 1997-10-29 Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie
PCT/EP1998/006849 WO1999021589A2 (fr) 1997-10-29 1998-10-29 Utilisation de vecteurs tels que adenovirus et/ou virus adeno-associes et/ou retrovirus et/ou herpesvirus et/ou liposomes et/ou plasmides comme vehicules d'informations genetiques relatives a l'aptitude des cellules de mammiferes a produire des agents pour le traitement de pathologies osseuses

Publications (1)

Publication Number Publication Date
EP1027076A2 true EP1027076A2 (fr) 2000-08-16

Family

ID=26041170

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98959810A Ceased EP1027076A2 (fr) 1997-10-29 1998-10-29 Utilisation de vecteurs tels que adenovirus et/ou virus adeno-associes et/ou retrovirus et/ou herpesvirus et/ou liposomes et/ou plasmides comme vehicules d'informations genetiques relatives a l'aptitude des cellules de mammiferes a produire des agents pour le traitement de pathologies osseuses

Country Status (5)

Country Link
US (1) US7105494B1 (fr)
EP (1) EP1027076A2 (fr)
AU (1) AU750803B2 (fr)
CA (1) CA2308511C (fr)
WO (1) WO1999021589A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2308511C (fr) 1997-10-29 2016-01-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Utilisation de cellules de mammiferes transfectees ou transduites pour traiter des maladies osseuses
WO2001082973A2 (fr) * 2000-04-28 2001-11-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vecteurs viraux et non viraux en tant que vehicules d'administration de transgenes pour le traitement de pathologies osseuses
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
AU2002243307A1 (en) * 2000-11-08 2002-07-24 Tissuegene, Inc. Gene therapy using tgf-beta
EP1365769B1 (fr) 2001-02-06 2011-01-26 The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) Medicament destine au traitement de l'osteonecrose et a la gestion de patients etant predisposes a l'osteonecrose
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
JP2009534394A (ja) * 2006-04-21 2009-09-24 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 結合組織障害の治療
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
WO2018125970A1 (fr) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Adénovirus synthétiques ciblant un tissu osseux et utilisations correspondantes
US12478661B2 (en) 2017-10-03 2025-11-25 The Johns Hopkins University Lung cell treatments to prevent or treat disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032407A (en) 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US6090790A (en) * 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5168050A (en) * 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
US5858355A (en) 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
DE4339352A1 (de) 1993-11-18 1995-05-24 Univ Ludwigs Albert Verfahren zur Markierung von Zellen, mit diesem Verfahren markierte Zellen, Verwendung des Wildtyp-Adeno-assoziierten Virus zur Markierung von Zellen und Testkits zum Nachweis des Wildtyp-Adeno-assoziierten Virus in Zellen
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
GB9407135D0 (en) * 1994-04-11 1994-06-01 Aberdeen University And Plasma Treatment of osteoporosis
US5665350A (en) 1994-11-23 1997-09-09 University Of Massachusetts Medical Center Cell cycle dependent transplantation and ex vivo gene therapy
JPH10509873A (ja) * 1994-11-29 1998-09-29 ザ ユニバーシティ オブ クイーンズランド 治療薬
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5854202A (en) * 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
WO1997022623A1 (fr) * 1995-12-19 1997-06-26 Human Genome Sciences, Inc. Proteine antivirale d'osteologie
KR20000029998A (ko) 1996-08-13 2000-05-25 리스 데브라 케이. 발현벡터,세포,그리고혈소판조혈인자를제조하는방법
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
EP0890639A3 (fr) 1997-07-09 2001-10-10 Gesellschaft für biotechnologische Forschung mbH (GBF) CADN induit par BMP2 et sa utilisation
CA2308511C (fr) 1997-10-29 2016-01-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Utilisation de cellules de mammiferes transfectees ou transduites pour traiter des maladies osseuses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9921589A3 *

Also Published As

Publication number Publication date
US7105494B1 (en) 2006-09-12
AU750803B2 (en) 2002-07-25
WO1999021589A3 (fr) 1999-10-14
WO1999021589A2 (fr) 1999-05-06
CA2308511A1 (fr) 1999-05-06
AU1557999A (en) 1999-05-17
CA2308511C (fr) 2016-01-19

Similar Documents

Publication Publication Date Title
DE69118535T2 (de) Osteo-induktive pharmazeutische formulierungen
DE69733605T2 (de) In vivo gentransfermethoden zur wundheilung
DE69434122T2 (de) Osteogenisches produkt und verwendung
DE69830320T2 (de) Verwendung von Adenoviralen Vektoren, die PDGF oder VEGF exprimieren, ZUR HEILUNG VON GEWEBSDEFEKTEN UND ZUR INDUZIERUNG DER HYPERVASKULITÄT IN SÄUGERGEWEBEN
DE69533176T2 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
DE60023754T2 (de) Künstlicher kalciumphosphatknochen als osteokonduktives und biologisch abbauba res knochenersatzmaterial
DE69431295T2 (de) Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
DE69024970T2 (de) Verfahren zur herstellung eines werkstoffes für osteoplastik aus natürlichem knochengewebe sowie aus solchem verfahren gewonnenes material
DE3751887T2 (de) Osteoinduktive mittel
Roederer et al. Modification of retrograde degeneration in transected spinal axons of the lamprey by applied DC current
DE69927512T2 (de) Verwendung von op-1 zur herstellung einer pharmazeutischen zusammensetzung zur reparatur von nicht-gelenksknorpeldefekten eines säugers
DE69819329T2 (de) Kollagen-polysaccharid matrize zur wiederherstellung von knochen und knorpel
DE69434739T2 (de) Menschliche Knochen-morphogenetische Proteine zur Verwendung bei neuronaler Rehgeneration
DE69814352T3 (de) Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung
DE68918922T3 (de) Biologische Unterlage für Zellkulturen, bestehend aus durch Thrombin koagulierte Plasmaproteine, ihre Verwendung für die Keratinozytenkultur, deren Rückgewinnung und Transport für therapeutische Verwendungszwecke.
DE69418865T2 (de) Osteoblastswachstumfordernde zusammensetzungen die pdgf und vitamin-d enthalten
DE60123218T2 (de) Produkt zur biologischen bindegewebsverankerung an knochen
DE69535155T2 (de) Für gdnf-kodierende rekombinante adenoviren
EP1027076A2 (fr) Utilisation de vecteurs tels que adenovirus et/ou virus adeno-associes et/ou retrovirus et/ou herpesvirus et/ou liposomes et/ou plasmides comme vehicules d'informations genetiques relatives a l'aptitude des cellules de mammiferes a produire des agents pour le traitement de pathologies osseuses
DE60035035T2 (de) Injektion von autologem knochenmark in den herzmuskel
DE3779829T2 (de) Zubereitung zur stimulation der chondrozyten und des osteoblastes (ossein-hydroxyapatit-verbindung), verfahren zur herstellung und pharmazeutische produkten, die sie enthalten.
DE60000501T2 (de) Verwendung von melanomhemmendem faktor zur reparatur von knorpelgewebe und knochen
US20110280935A1 (en) Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
DE60226321T2 (de) Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
DE69832989T2 (de) Genetisch manipulierte Zellen die Knochenmorphogeneseproteine exprimieren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000522

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090530